疏风解毒胶囊联合抗生素治疗社区获得性肺炎的临床观察
|
摘要
目的观察疏风解毒胶囊联合抗生素治疗社区获得性肺炎(CAP)的临床疗效。方法患者120例随机分为两组,对照组规范化治疗,观察组加用疏风解毒胶囊。观察两组患者治疗后临床效果。结果与对照组比较,观察组主要临床症状恢复时间明显缩短(P <0.05),且白细胞计数(WBC)、NE、C反应蛋白(CPR)、PCT在治疗后第3日明显降低(P <0.05),第7日基本恢复正常。影像检查表明治疗组肺部炎症病灶吸收率高于对照组(P <0.05)。两组均未见不良反应发生。结论疏风解毒胶囊联合抗生素治疗CAP,能有效减轻临床症状,加速感染指标的恢复。
Objective: To observe the clinical effect of Shufeng Jiedu Capsule combined with piperacillin tazobartan in the treatment of community acquired pneumonia(CAP). Methods: 120 patients were randomly divided into two groups,the control group were treated with standardized treatment,and the observation group were given Shufeng Jiedu Capsule on the basis of the control group.The clinical effect of two groups of patients after treatment were observed. Results: Compared with the control group,the recovery time of major clinical symptoms in the observation group was significantly shortened(P < 0.05),and the white blood cell count(WBC) NE,c-reactive protein(CRP),and PCT were significantly reduced on the third day after treatment(P < 0.05),and basically returned to normal on the seventh day. Imaging examination showed that the absorption rate of pulmonary inflammatory lesions in the treatment group was higher than that in the control group(P < 0.05). No adverse reactions were observed in the two groups. Conclusion: Shufeng Jiedu Capsule combined with antibiotics in the treatment of CAP can effectively reduce clinical symptoms and accelerate the recovery of infection indicators.
Objective: To observe the clinical effect of Shufeng Jiedu Capsule combined with piperacillin tazobartan in the treatment of community acquired pneumonia(CAP). Methods: 120 patients were randomly divided into two groups,the control group were treated with standardized treatment,and the observation group were given Shufeng Jiedu Capsule on the basis of the control group.The clinical effect of two groups of patients after treatment were observed. Results: Compared with the control group,the recovery time of major clinical symptoms in the observation group was significantly shortened(P < 0.05),and the white blood cell count(WBC) NE,c-reactive protein(CRP),and PCT were significantly reduced on the third day after treatment(P < 0.05),and basically returned to normal on the seventh day. Imaging examination showed that the absorption rate of pulmonary inflammatory lesions in the treatment group was higher than that in the control group(P < 0.05). No adverse reactions were observed in the two groups. Conclusion: Shufeng Jiedu Capsule combined with antibiotics in the treatment of CAP can effectively reduce clinical symptoms and accelerate the recovery of infection indicators.
引文
[1]Jain S.Community-acquired pneumonia requiring hospitalization among U.S.adults[J].N Engl J Med,2015,373(5):415-427.
[2]Takaki M.High incidence of community-acquired pneumonia among rapidly aging population in Japan:a prospective hospital-based surveillance[J].Jpn J Infect Dis,2014,67(4):269-275.
[3]Takayanagi N.Etiology and outcome of community-acquired pneumonia in relation to age and severity in hospitalized adult patients[J].Nihon Kokyuki Gakkai Zasshi,2006,44(12):906-915.
[4]张连国,滕国杰,周玉涛.疏风解毒胶囊治疗老年社区获得性肺炎患者的疗效评价[J].中国医药导刊,2014,16(12):1471-1474.
[5]胡蓉,王丽华,张珺珺,等.疏风解毒胶囊治疗急性咽炎风热证的临床观察[J].药物评价研究,2014,37(5):460-462.
[6]张亚平,林颖,闵珉,等.疏风解毒胶囊治疗急性病毒性上呼吸道感染对患者血清淀粉样蛋白A的影响[J].中国病原生物学杂志,2014,9(8):734-736.
[7]蓝海涛,赵昕.疏风解毒胶囊在抗感染治疗中的研究进展[J]陕西中医,2017,38(9):1317-1318.
[8]中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,4(39).
[9]Welte T.Community-acquired pneumonia:a disease of the elderly[J].Z Gerontol Geriatr,2011,44(4):221-228.
[10]Guan X.Pneumonia incidence and mortality in Mainland China:systematic review of Chinese and English literature,1985-2008[J].PLoS One,2010,5(7):e11721.
[11]Luna CM.The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia[J].Ann Am Thorac Soc,2016,13(9):1519-1526.
[12]赵克昌,王皓,吴世乐.降钙素原与白细胞计数及肿瘤坏死因子α和C反应蛋白对肠梗阻患者肠坏死早期诊断的价值[J].中国医药,2017,12(12):1853-1856.
[13]Lee JY,Hwang SJ,Shim JM,et al.Clinical significance of serum procalcitonin in patients with community-acquiredlobar pneumonia[J].Korean J Lab Med,2010,30(4):406-413.
[14]王传海,李承红.老年社区获得性细菌性肺炎患者降钙素原的测定及其意义[J].海南医学,2016,(27)18:2969-2970.
[15]黎伟.血清PCT在老年社区获得性细菌性肺炎的临床应用价值[J].中国微生态学杂志,2015,27(7):840-843.
[16]Liu D.Prognostic value of procalcitonin in pneumonia:A systematic review and meta-analysis[J].Respirology,2016,21(2):280-288.
[17]李得民,唐诗环.中医药防治社区获得性肺炎的文献研究[J]中国中药杂志,2016,42(8):1418-1422.
[18]任庆伟.疏风解毒胶囊联合抗生素治疗慢性支气管炎急性加重期临床观察[J].中国中医急症,2016,8(8):1571-1573.
[19]刘静,马莉.疏风解毒胶囊解热作用机制研究[J].中草药,2016,47(12):2040-2043.
[20]刘冉,李宣霖,王憭瑶,等.疏风解毒胶囊联合抗生素治疗社区获得性肺炎的Meta分析与GRADE评价[J].中医杂志,2018,59(19):1656-1659.
[2]Takaki M.High incidence of community-acquired pneumonia among rapidly aging population in Japan:a prospective hospital-based surveillance[J].Jpn J Infect Dis,2014,67(4):269-275.
[3]Takayanagi N.Etiology and outcome of community-acquired pneumonia in relation to age and severity in hospitalized adult patients[J].Nihon Kokyuki Gakkai Zasshi,2006,44(12):906-915.
[4]张连国,滕国杰,周玉涛.疏风解毒胶囊治疗老年社区获得性肺炎患者的疗效评价[J].中国医药导刊,2014,16(12):1471-1474.
[5]胡蓉,王丽华,张珺珺,等.疏风解毒胶囊治疗急性咽炎风热证的临床观察[J].药物评价研究,2014,37(5):460-462.
[6]张亚平,林颖,闵珉,等.疏风解毒胶囊治疗急性病毒性上呼吸道感染对患者血清淀粉样蛋白A的影响[J].中国病原生物学杂志,2014,9(8):734-736.
[7]蓝海涛,赵昕.疏风解毒胶囊在抗感染治疗中的研究进展[J]陕西中医,2017,38(9):1317-1318.
[8]中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,4(39).
[9]Welte T.Community-acquired pneumonia:a disease of the elderly[J].Z Gerontol Geriatr,2011,44(4):221-228.
[10]Guan X.Pneumonia incidence and mortality in Mainland China:systematic review of Chinese and English literature,1985-2008[J].PLoS One,2010,5(7):e11721.
[11]Luna CM.The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia[J].Ann Am Thorac Soc,2016,13(9):1519-1526.
[12]赵克昌,王皓,吴世乐.降钙素原与白细胞计数及肿瘤坏死因子α和C反应蛋白对肠梗阻患者肠坏死早期诊断的价值[J].中国医药,2017,12(12):1853-1856.
[13]Lee JY,Hwang SJ,Shim JM,et al.Clinical significance of serum procalcitonin in patients with community-acquiredlobar pneumonia[J].Korean J Lab Med,2010,30(4):406-413.
[14]王传海,李承红.老年社区获得性细菌性肺炎患者降钙素原的测定及其意义[J].海南医学,2016,(27)18:2969-2970.
[15]黎伟.血清PCT在老年社区获得性细菌性肺炎的临床应用价值[J].中国微生态学杂志,2015,27(7):840-843.
[16]Liu D.Prognostic value of procalcitonin in pneumonia:A systematic review and meta-analysis[J].Respirology,2016,21(2):280-288.
[17]李得民,唐诗环.中医药防治社区获得性肺炎的文献研究[J]中国中药杂志,2016,42(8):1418-1422.
[18]任庆伟.疏风解毒胶囊联合抗生素治疗慢性支气管炎急性加重期临床观察[J].中国中医急症,2016,8(8):1571-1573.
[19]刘静,马莉.疏风解毒胶囊解热作用机制研究[J].中草药,2016,47(12):2040-2043.
[20]刘冉,李宣霖,王憭瑶,等.疏风解毒胶囊联合抗生素治疗社区获得性肺炎的Meta分析与GRADE评价[J].中医杂志,2018,59(19):1656-1659.